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Abstract
Despite the increasing numbers of travel-acquired dengue, few studies have assessed virologic markers of the disease in
non-endemic populations. We examined the kinetics of diagnostic markers and their associations with clinical parameters in
93 patients with travel-acquired dengue fever. Kinetics analyses suggested a longer average duration for viremia (9 days,
CI95%: 8–10) and non-structural protein 1 (NS1) antigenemia (15 days, CI95%: 12–20) than reported in endemic populations.
While none of the tests sufficed alone, the best diagnostic coverage was achieved by combining antibody detection with
RNA or NS1 testing. Studied by regression models, early relative levels of viremia and NS1 antigenemia proved to be
significantly associated with several clinical parameters: high viremia predicted greater likelihood and increased length of
hospitalization, the degree of NS1 antigenemia correlated positively with hematocrit and liver transaminases, and both
viremia and NS1 antigenemia levels negatively with platelet counts in follow-up. Levels of viremia and NS1 antigenemia
may serve as predictors of the clinical manifestations in travel-acquired dengue.
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Introduction
Dengue is the most common mosquito-borne viral disease
worldwide, causing 50–100 million infections annually [1]. It is
endemic in most tropical and subtropical parts of the world,
especially in urban areas, many of which are popular travel
destinations. Accordingly, ongoing dengue epidemics have man-
ifested themselves as an increasing number of infections not only in
endemic populations, but also among travelers returning from the
dengue endemic areas [2,3].
The laboratory diagnostics of dengue virus (DENV) infections is
currently based on virus isolation, and detection of DENV RNA,
non-structural protein 1 (NS1), and DENV-specific antibodies
[4,5]. Few laboratories can provide the full range, yet none of
these assays covers the entire disease period [4,5]. For a rational
choice and timing of the tests, the kinetics of the various diagnostic
markers needs to be understood. For efficient diagnostics, it
appears that two or more methods should be combined.
The clinical outcome of DENV infections ranges in severity
from asymptomatic or non-specific febrile illness to classical
dengue fever and to severe dengue characterized by one or more
of the following: plasma leakage, severe bleeding, and severe organ
impairment [5]. Severe dengue infections should be treated in
dedicated high-dependency units, where a mortality of less than
1% can be achieved [3]. In travelers, dengue is rarely a life-
threatening disease; yet, severe forms of disease are also seen [6,7].
Epidemiologic studies have identified several risk factors for
severe disease, including previous exposure to heterologous DENV
serotype, infection with certain viral strains and serotypes, young
age, female sex, and certain gene variants of the host [8–12]. A
high degree of serum viremia and NS1 antigenemia have been
associated with a more severe disease outcome in endemic
populations [13–17]. Differing results have also been reported
[18,19], though, and studies in travel-acquired dengue have been
lacking.
Recently, the importance of early diagnosis and risk prediction
of clinical outcome have been emphasized [3]. In addition to
endemic areas, these should also be studied among travelers who
may differ from endemic populations in a number of essential
respects, such as lack of previous immunity against heterotypic
serotypes, dissimilarity in pre-existing immunity against other
flaviviruses (e.g. Japanese encephalitis, tick-borne encephalitis,
yellow fever), variety of infecting DENV sero- and genotypes, as
well as age and genetic background.
The present study investigated the clinical and diagnostic data
of 93 Finnish travelers with acute dengue infections, aiming at (1)
describing the kinetics of DENV viremia, NS1 antigenemia, and
DENV-specific antibodies, (2) assessing their use in diagnostics as
combinations, and (3) examining the potential correlation between
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diagnostic markers (viremia and NS1 antigenemia) and clinical
parameters in travel-acquired dengue.
Methods
Ethics statement
As a retrospective registry study based solely on patient files and
routine, archived blood samples, instead of patient consent and an
ethics approval, the study required research clearances from the
institutes and the Ministry of Social Affairs and Health.
Accordingly, the study was approved by the research boards of
the Department of Internal Medicine of Helsinki University
Central Hospital, Helsinki University Hospital laboratory (HUS-
LAB), and the Ministry of Social Affairs and Health.
Study design
In Finland, laboratory diagnostics of dengue has been based on
serological testing performed in a single laboratory for all the
patients throughout the country (HUSLAB, Helsinki University
Central Hospital). For this study, we retrospectively recorded data
on all the DENV IgM-positive patients in Finland 1999–2008 (a
total of 154 cases). From these patients, all samples taken within 21
days since illness onset were collected, including the early IgM-
negative sera. Four patients were excluded due to suspicion of false
positive IgM. This group consisted of one published case of
Japanese encephalitis [20], one laboratory-confirmed tick-borne
encephalitis (strong positive anti-TBE IgM in serum and
cerebrospinal fluid along with a characteristic clinical picture,
and only weakly positive serum anti-dengue IgM), and 2 patients
who did not show diagnostic seroconversion in serial samples.
After additionally excluding those with insufficient clinical
information (57 patients), the data comprised a total of 139
samples from 93 patients (1–3 samples per patient). The first
samples from a subgroup of patients (72/93) were evaluated
previously [21]; these early-phase sera were included in the present
study along with convalescent samples for analyses of the kinetics
of virologic markers, and with additional clinical data for studying
the associations between virologic markers and clinical parame-
ters.
The clinical and laboratory data were analyzed by two kinds of
statistical approaches: (1) those exploring the kinetics of diagnostic
markers either with a single-test approach or as combinations of
two tests, and (2) those examining the associations between
virologic markers and clinical parameters. For analyses of the
kinetics, we included all 139 serum samples taken within 21 days
since the onset of symptoms (93 patients, 1–3 samples each). For
the association analyses, we included a subgroup of 89 patients
with data on the following potential confounding factors: age, sex,
day of illness, presence of co-infections and chronic diseases, which
were controlled in the statistical analyses.
Collection of clinical data
The following clinical information was retrieved retrospectively
from medical records: demographic characteristics (age, gender,
country of birth), chronic diseases (long-lasting condition that can
be controlled but not cured, such as diabetes mellitus), previous
vaccinations against other flaviviruses, travel destination, symp-
toms, results of routine laboratory investigations, presence of co-
infections (additional diagnosis of an acute infectious disease other
than dengue), possible hospitalization and its length. The date of
the onset of symptoms was designated as day 1. Laboratory
parameters were classified as being normal, decreased, or elevated
according to current reference values. The severity of the cases was
assessed according to the WHO dengue classification criteria valid
at the time of data collection [22].
Virological and serological assays
The anti-DENV IgM tests were performed with a commercial
enzyme immunoassay (EIA) (Focus Technologies) following
manufacturer’s instructions. The anti-DENV IgGs were deter-
mined by an in-house immunofluorescence assay as previously
described [23]. The tests were carried out as dilution series of 1:10
to 1:640, employing acetone-fixed DENV-3 infected Vero E6 cells
as the antigen.
RNA extraction, the detection of RNA by real-time reverse
transcription polymerase chain reaction (RT-PCR) (tested in 132
samples), and of the NS1 antigen by EIA (tested in 135 samples)
were performed as previously described [21]. The serum aliquots
were stored at 270uC and 220uC for RNA and NS1 detection,
respectively. The RNA extractions were carried out from 100 ml of
serum specimens by the QIAamp Viral RNA Mini Kit (Qiagen)
according to manufacturer’s instructions. For the DENV NS1
antigen detection we used the commercial Platelia Dengue NS1
Ag EIA assay (Bio-Rad) adhering to manufacturer’s instructions.
Some of the NS1 Ag tests (69/135) and one-step real-time RT-
PCRs (69/132) were carried out separately prior to this study [21].
For the 63 sera tested for RNA for this study only, the Stratagene
thermocycler was used instead of the ABI Prism 7700 Sequence
Detection System. The comparability and reproducibility of the
results obtained with the two pieces of equipment was ascertained
by means of appropriate internal controls. The infecting DENV
Table 1. Background characteristics of the 93 travelers
with dengue.
% N
Gender
Male 56 52/93
Female 44 41/93
Ethnic origin
Finnish 88 82/93
Other 12 11/93
Chronic diseasesa
Generally healthy 79 72/91
Chronic diseases 21 19/91
History of previous flavivirus vaccinationb
Japanese encephalitis vaccine 11 10/92
Yellow fever vaccine 20 18/92
Tick-borne encephalitis vaccine 1 1/92
Any of the above 22 20/92
Geographic region visitedb
South-East Asia 50 46/92
South Central Asia 21 19/92
Central America and Caribbean 14 13/92
Sub-Saharan Africa 8 7/92
South America 7 6/92
Southwest Asia 1 1/92
The median age of patients was 37 years (interquartile range: 28 to 45 years).
aData missing for two patients.
bData missing for one patient.
doi:10.1371/journal.pone.0065900.t001
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serotype was determined by virus isolation, DENV-typing RT-
PCR [24] and consequent sequencing [21,25], or by direct
sequencing of RT-PCR products [24,26] obtained directly from
serum samples.
The default setting for Finnish travelers is a primary infection,
as the vast majority are – apart from a vaccinated minority –
flavivirus naı¨ve. As high levels of IgG with low or even absent IgM
levels during the early acute phase have been associated with
secondary infections [5], for the purpose of this study, cases with
positive RT-PCR result, IgG titers $80 (IFA), and a negative IgM
(IgM-EIA) test in the acute phase were considered as possible
secondary cases.
Statistical analyses
All statistical analyses were performed with R software [27].
The kinetics of serum DENV RNA, NS1 antigen, and DENV-
specific antibodies were studied using generalized additive mixed
models (GAMM) [28]. In all models, a smoothing spline of the
number of days since illness onset was employed as the
explanatory variable. Two kinds of univariate models were
formed: (1) those with Gaussian error distributions and an identity
link function, where continuous values of diagnostic markers
(inverse cycle threshold [ct] -value, NS1 ratio, IgM index, and
log10-transformed IgG titre) were used as dependent variables, and
(2) those with binomial error distributions and a logit link function
with binary outcomes (negative/positive) of the four diagnostic
tests as dependent variables. Similarly, we studied the kinetics of
different combinations of two diagnostic tests over the course of
illness, using GAMM with binomial error distribution and a logit
link function, the classes of the dependent variable being negative
in both tests/positive in either of the tests.
Associations between virologic markers (serum DENV RNA
and NS1 antigen) and clinical parameters (routine laboratory test
results, symptoms during follow-up, likelihood and length of
hospitalization) were studied by regression models. The full model
had the clinical parameter as the dependent variable, and
potential confounding factors (age, sex, day of illness, presence
of co-infections and chronic diseases) as explanatory variables.
Each of the virologic markers (serum DENV RNA and NS1
antigen) were included in the full model in turn, and a model set
constituting 95% of Akaike weights of all models nested within the
full model was then averaged [29] using MuMIN package [30] in
R software. Gaussian error distributions, an identity link function,
and continuous diagnostic explanatory variables (the inverse ct-
value from RT-PCR [cut-off ct-value – sample ct-value], NS1
ratio from antigen EIA) were applied to models with continuous
values of routine laboratory findings as dependent variables. A
Poisson error distribution adjusted for overdispersion, a log link
function, and continuous diagnostic variables were used in models
studying the duration of hospitalization. For models examining
binary dependent variables (likelihood of abnormal laboratory
findings/occurrence of different symptoms/hospitalization), we
employed binomial error distributions, a logit link function, and
binary diagnostic outcomes (serum DENV RNA/NS1 positivity).
Table 2. Clinical characteristics of the 93 travelers with
dengue.
% N
Clinical symptoms
Fever 93 86/92
Rash 71 65/92
Headache 64 59/92
Myalgia 55 51/92
Fatigue 51 47/92
Other gastrointestinal symptoms 46 42/92
Nausea 45 41/92
Arthralgia 34 31/92
Respiratory symptoms 27 25/92
Hemorrhagic manifestations 24 22/92
Vomiting 24 22/92
Retro-orbital pain 17 16/92
Pruritus 9 8/90
Shock 0 0/92
Routine laboratory findings in follow-upa
Anaemia (,134/117 g/L) 9 5/56
Elevated Hb (.167/155 g/L) 13 11/87
Low Hcr (,39%/35%) 9 5/56
Elevated Hcr (.50%/46%) 8 7/87
Leukopenia (,3.46109/L) 67 59/88
Thrombocytopenia (,1506109/L) 78 68/87
Elevated AST (.45/35 U/L) 78 49/63
Elevated ALT (.70/45 U/L) 61 51/83
Elevated creatinine (.100/90 mmol/L) 25 10/40
Patients positive for the various diagnostic testsb
PCR 74% 67/90
NS1 79% 72/91
IgMc 100% 93/93
IgG 98% 91/93
Serotype identified
DENV-1 26 24/93
DENV-2 8 7/93
DENV-3 24 22/93
DENV-4 3 3/93
Not known 40 37/93
Co-infectionsd
At least one co-infection 19 17e/91
Gastrointestinal infection 9 8/91
Respiratory tract infection 4 4/91
Urinary tract infection 2 2/91
Other bacterial disease 2 2/91
Malaria 2 2/91
Other parasitic disease 1 1/91
Hospitalization 79 73f/92
aReference values for males/females in parentheses.
bAt least once during the 21 days since illness onset. The timing of serum
sampling was not standardized.
cSelection criterion for entering the study.
dDiagnosed according to current practice.
eOf these patients, 9/17 (53%) were positive for PCR or NS1 at some point. The
patients negative for PCR and NS1 provided samples on illness days 6–21.
fDuration of hospitalization: median 4 days, interquartile range 3 to 6 days.
Abbreviations: ALT, alanine transaminase; AST, aspartate transaminase; DENV,
dengue virus; Hb, hemoglobin; Hcr, hematocrit.
doi:10.1371/journal.pone.0065900.t002
Table 2. cont.
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Explanatory variables were considered statistically significant (on
0.05 level), if the 95% confidence intervals of their coefficients
excluded zero.
Results
Patient characteristics
Table 1 and Table 2 summarize the background characteristics
and clinical data of the study population. The majority of the
patients were Finnish adults with no underlying chronic diseases.
Most of the dengue cases were acquired in Asia (72%).
All patients were classified as having an uncomplicated dengue
infection. Most of the cases were categorized as primary infections.
Only three patients were considered to have a probable secondary
infection: in the first sample they had a considerable anti-DENV
IgG level concomitantly with a negative anti-DENV IgM, yet their
samples were positive for DENV-RNA. No other cases with a
considerable early IgG and low or non-existent IgM were
detected. None of the suspected secondary cases had received
flaviviral vaccines in the past.
The majority (79%) were admitted to hospital, the mean length
of hospitalization being 4.5 (SD 2.5) days. Their treatment was
symptomatic, and some patients were also given antimicrobials,
either because they were initially suspected to have a bacterial
infection or because a simultaneous co-infection (19% [17/91] of
the cases) was diagnosed. The most common co-infection was
bacterial gastroenteritis.
All four DENV serotypes were detected in this patient
population (Table 2). DENV-1 (24/56) and DENV-3 (22/56)
were the predominant serotypes, accounting for 82% (46/56) of
cases with identified serotype.
Kinetics of diagnostic markers
Figure 1 shows the kinetics of plasma viremia, NS1 antigen-
emia, and DENV-specific IgM and IgG antibodies in the 93
patients studied. DENV RNA and NS1 antigen were detected
already on the 2nd day of illness (the earliest serum samples), with a
probability of 91% (95% CI: 82–96% for PCR positivity and 80–
96% for NS1 positivity) (Figure 1E, 1F). On the 7th day of illness,
65% (95% CI: 54–74%) of the sera were still positive for DENV
RNA, and 80% (95% CI: 71–87%) were positive for NS1. Patients
were likely to remain PCR positive up to illness day 9 (95% CI:
day 8–10), whereas NS1 positivity would last longer, until illness
day 15 (95% CI: day 12–20). On day 21, none of the sera proved
positive for DENV RNA, while 20% were still positive for NS1
(Figure 1E, 1F).
During the first 12 days of illness, all serum samples from
patients with DENV-1 infection (n = 35), but only 69% (n = 32) of
those from patients with DENV-3 infection were NS1 positive
(p = 0.0003, Fisher’s exact test). In the 13 samples taken after day
12, this difference was no longer seen. The kinetics of viremia
showed no serotype-dependent differences (data not shown).
Figure 2 shows the sensitivities for the combinations of two
diagnostic tests over the first three weeks of illness. When RNA
detection was combined with IgM detection, only 1% (1/120) of
the serum samples remained negative (the negative sample taken
on illness day 14). The combination of NS1 and IgM detection
remained negative in 3% (4/120) of the samples. Although not
primarily intended for identifying acute infection, the combina-
tions with IgG detection were also studied. When either RNA or
NS1 tests were used together with IgG detection, 2% (3/129) or
3% (4/130) of the samples were negative, respectively. When
combining IgM and IgG detection, the results proved negative for
10% (12/124) of the samples; when using RNA and NS1 detection
together, 25% (32/127) proved negative.
Associations between virologic markers and clinical
parameters
Associations between virologic markers (serum viremia/NS1
antigenemia) and clinical parameters were studied with regression
models in a subgroup of 89 patients who provided data on the
following potential confounding factors controlled in the analyses
(age, sex, day of illness, presence of co-infections and chronic
diseases). All associations reported below were statistically signif-
icant on the 0.05 level when confounding factors were controlled
for. Table S1, and Figures S1 and S2 show the associations
between virologic markers and clinical parameters. Tables S2 and
S3 provide the averaged coefficients of all explanatory variables
and their 95% CIs for all models studied.
Associations between viremia and clinical
parameters. While controlling for potential confounding fac-
tors, e.g. day of illness, relative levels of DENV RNA in the first
serum sample correlated negatively with leukocyte and platelet
nadirs in follow-up (Figure S1, Table S3). In addition, overall PCR
positivity at the time of presentation predicted a higher probability
of leukopenia, thrombocytopenia, and elevated alanine and
aspartate transaminases (ALT, AST) during the illness (Tables
S1 and S2).
No associations were found between initial DENV RNA
positivity and the various symptoms during the illness (Table S2).
Patients found DENV RNA positive at the time of admission
proved more likely to be hospitalized than RNA negative patients
(Tables S1 and S2). Furthermore, a high relative amount of serum
DENV RNA at the time of presenting to hospital increased both
the probability and duration of hospitalization (Figure S2, Table
S3).
Associations between NS1 antigenemia and clinical
parameters. Relative levels of NS1 antigen at the time of
admission correlated negatively with leukocyte and platelet nadirs,
and positively with maximum levels of hemoglobin, hematocrit
and liver transaminases (AST, ALT) in follow-up (Figure S1, Table
S3). Overall NS1 positivity at the time of hospital admission was
associated with a higher probability of leukopenia, thrombocyto-
penia, elevated ALT, and AST (Tables S1 and S2). The odds
ratios for developing leukopenia, thrombocytopenia, or elevated
ALT, were at least twice as high for RNA positive as for NS1
positive patients (Table S1).
NS1 positivity at the time of admission was found to be
associated with fatigue and abdominal pain/diarrhea over the
course of illness (Table S2).
No association was found between early NS1 positivity or
relative amount of serum NS1 and probability/duration of
hospitalization (Tables S1, S2, S3, Figure S2).
Discussion
The need for better diagnostics of dengue and prediction of
disease outcome is becoming increasingly urgent [3]. On account
of differences in patient characteristics, separate data on endemic
populations and travelers from non-endemic regions are essential.
Our previous study suggested that the kinetics of DENV viremia
and NS1 antigenemia may differ in traveler populations. This
study further explores the kinetics of diagnostic markers, as well as
their use as combinations, and correlations with clinical param-
eters in travel-acquired dengue.
Virologic Markers in Travelers’ Dengue
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Kinetics of viremia
The current data suggest a longer span of serum viremia in
travel-acquired dengue than that reported in endemic populations
[4,5,16,17]. Viral RNA was detectable on average until illness day
9; in endemic settings an average duration of 5 to 7 days has been
reported [4,5,16,17]. This finding might be related to the high
proportion of primary infections among travelers, the clearance of
viremia being slower in primary than secondary infections [16,17].
Kinetics of NS1 antigenemia
NS1 antigen was already detectable in the earliest serum
samples, consistent with previous studies in endemic areas [31–
33]. However, as in viremia, the NS1 positivity lasted longer than
that reported in endemic populations. This might be due to slower
clearance of the antigen in primary infections, or a higher
sensitivity of the assay in the absence of pre-existing anti-NS1
antibodies. Compared to an average duration of 5 to 7 days
Figure 1. Kinetics of diagnostic markers. Relative amounts (A–D) and the probability of a positive result (E–H) of DENV-RNA, NS1 protein, and
DENV specific IgM and IgG antibodies in the serum samples of 93 patients with acute dengue fever. Solid lines indicate predicted means (A–D), and
probabilities (E–H) from generalized additive mixed models (GAMM), and dashed lines their 95% confidence intervals. In A–D, the circles serve to
illustrate individual observations; in E–H, the circles show the positive/negative test results at each given time point, the size of the circle being
proportional to the number of observations.
doi:10.1371/journal.pone.0065900.g001
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recorded in endemic settings [5,19,31,32], NS1 positivity lasted on
average until illness day 15, the span of NS1 antigen detection
being also significantly longer than that of serum viremia.
Over the first 12 days of illness, NS1 positivity was found more
often in patients infected with DENV-1 than DENV-3, consistent
with some previous studies [19,34]. The NS1 EIA test is supposed
to detect NS1 antigens of all serotypes equally [31]; a better
sensitivity for serotype 1 has been suggested, however [17].
Altogether, the long detection span of NS1, availability of the test,
and high specificity in comparison to antibody testing [31,35]
make the assessment of NS1 a useful tool for diagnosing traveler’s
dengue.
Diagnostic coverage
When scrutinizing the first 3 weeks after onset, none of the
diagnostic methods could alone serve as a sufficient diagnostic tool
for the whole time period, as expected. Combining RNA or NS1
detection and antibody testing resulted in a high overall sensitivity,
which accords with results from previous studies [19,21,33,36,37].
In settings where RNA detection is not readily available, the
combination of IgM and NS1 appears to be a feasible approach.
The advantages of NS1 over RNA detection are low cost and ease
of testing. Moreover, the long detection span of NS1 antigen
enhances diagnostic specificity in the later phase of the disease.
Virologic markers and clinical picture
Dengue in travelers is considered mostly a mild disease [6], yet
severe forms of the disease are occasionally seen [7]. None of our
cases were classified as dengue hemorrhagic fever or dengue shock
syndrome according to the WHO criteria valid at the time of data
collection. A significant proportion of the study patients were
hospitalized, however; the decision was taken on the basis of the
clinicians’ evaluation of the patients’ general condition. In Finland
it is customary to hospitalize febrile travelers whenever there is any
reason to believe that their clinical status may get worse, regardless
of whether a diagnosis has been established or not. In most cases
dengue was not diagnosed until after the patient was admitted to
hospital.
Despite the fact that the dengue cases were predominantly mild,
regression analyses revealed several associations between the
relative levels of virologic markers (DENV RNA and NS1) and the
various clinical parameters studied. The initial levels of viremia
predicted both likelihood and duration of hospitalization. Notably,
the clinicians were unaware of their patients’ viremia (or NS1
antigenemia) status at the time of illness, and the number of days
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from the onset of illness was controlled in the statistical analyses; if
not, both of these could have had a confounding effect on the
associations observed.
The initial levels of NS1 antigenemia were not associated with
hospitalization, but correlated positively with some central
laboratory parameters, such as hematocrit and liver transaminases.
Notably, both serum viremia and NS1 antigenemia levels
correlated negatively with platelet counts over the course of illness.
Studies conducted in endemic settings have related high serum
viremia and NS1 antigenemia with severe dengue [13–17]; this
relation has not been confirmed in some other studies, though
[18,19]. To our knowledge, correlations between virologic and
clinical markers have not previously been assessed in travelers. To
study these associations, a prospective study design with
standardized data collection would have been superior to the
retrospective approach. Due to the relatively low incidence of
dengue among Finnish travelers, a prospective study would have
been difficult to conduct in the current setting, though. One of the
limitations of the retrospective research approach was the lack of
comprehensive data on pre-existing flaviviral immunity. However,
other known potential confounding factors (day of illness, and age,
sex, and presence of co-infections and chronic diseases) were
controlled in the analyses exploring the correlations between
virologic and clinical markers. Despite infections being predom-
inantly mild in this study, the observed correlations with clinical
parameters (e.g. hematocrit and thrombocytopenia) suggest that
viremia and NS1 antigenemia may serve as predictors of the
clinical manifestations in travel-acquired dengue.
Conclusions
This study suggests a longer average duration of serum viremia
and NS1 antigenemia in travel-acquired dengue than that
observed in endemic areas, emphasizing the importance of
carrying out individual studies among different patient popula-
tions. Our results highlight the importance of combining
diagnostic tests, such as NS1 and IgM detection, to provide better
diagnostic coverage. The early appearance and long detection
span of NS1, easy performance and rapidity of the test, as well as
high specificity for dengue viruses as compared to antibody testing
make the assessment of NS1 a feasible tool for diagnosing
traveler’s dengue. Both viremia and NS1 antigenemia showed
correlation with several clinical parameters, suggesting a potential
role in predicting disease outcome in traveler patients.
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Figure S1 Correlations between virologic markers and
laboratory parameters. Associations between relative
amounts of DENV RNA and NS1 antigen in the first serum
sample, and the minimum/maximum values of hemoglobin,
leukocytes, platelets, ALT, and AST during follow-up. Lines
indicate predictions from averaged linear models (thick line =
statistically significant, thin line = non-significant association),
and open symbols the observed data. In hemoglobin plots, solid
line and open dots indicate the predictions and data for women,
dashed lines and open squares those for men.
(EPS)
Figure S2 Correlations between virologic markers and
hospitalization. Associations between relative amounts of serum
DENV RNA/NS1 antigen at the time of presenting to hospital
and probability and length of hospitalization. The circles indicate
the degree of serum viremia/NS1 antigenemia for individual
patients at the time of presenting to hospital and the choice of
treatment place (out-patient/hospitalized)/length of hospitaliza-
tion. The size of the circles is presented in proportion to the
number of observations.
(EPS)
Table S1 Odds ratios (OR) and predicted occurrence of
abnormal laboratory values during follow-up depending
on initial RNA or NS1 positivity.
(DOCX)
Table S2 Parameter estimates and their 95% confi-
dence intervals from averaged model sets exploring the
connection between the initial DENV RNA/NS1 antigen
positivity and the probabilities of abnormal clinical
parameters, hospitalization, and different symptoms
during follow-up.
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Table S3 Parameter estimates and their 95% confi-
dence intervals from averaged model sets exploring the
connection between initial amounts of serum DENV
RNA/NS1 antigen and clinical parameters in follow-up.
(DOCX)
Acknowledgments
The authors wish to thank Minna Ulmanen and Kirsti Ra¨iha¨ for technical
assistance.
Author Contributions
Conceived and designed the experiments: EOE EMK LV EH OV AK.
Performed the experiments: EMK EH. Analyzed the data: LV.
Contributed reagents/materials/analysis tools: OV. Wrote the paper:
EOE EMK LV EH OV AK. Collected clinical data: EOE AK.
References
1. WHO. (2012) Dengue and severe dengue. Factsheet No 117, revised January
2012. Geneva, World Health Organization.
2. Wilder-Smith A, Schwartz E. (2005) Dengue in travelers. N Engl J Med 353:
924–932.
3. Simmons CP, Farrar JJ, Nguyen v, Wills B. (2012) Dengue. N Engl J Med 366:
1423–1432.
4. Peeling RW, Artsob H, Pelegrino JL, Buchy P, Cardosa MJ, et al. (2010)
Evaluation of diagnostic tests: Dengue. Nat Rev Microbiol 8: S30–8.
5. WHO. (2009) Dengue: Guidelines for diagnosis, treatment, prevention and
control – New edition. World Health Organization.
6. Baaten GG, Sonder GJ, Zaaijer HL, van Gool T, Kint JA, et al. (2011) Travel-
related dengue virus infection, The Netherlands, 2006–2007. Emerg Infect Dis
17: 821–828.
7. Wichmann O, Gascon J, Schunk M, Puente S, Siikamaki H, et al. (2007) Severe
dengue virus infection in travelers: Risk factors and laboratory indicators. J Infect
Dis 195: 1089–1096.
8. Halstead SB. (1970) Observations related to pathogenesis of dengue hemor-
rhagic fever. VI. Hypotheses and discussion. Yale J Biol Med 42: 350–362.
9. Khor CC, Chau TN, Pang J, Davila S, Long HT, et al. (2011) Genome-wide
association study identifies susceptibility loci for dengue shock syndrome at
MICB and PLCE1. Nat Genet 43: 1139–1141.
10. Anders KL, Nguyet NM, Chau NV, Hung NT, Thuy TT, et al. (2011)
Epidemiological factors associated with dengue shock syndrome and mortality in
hospitalized dengue patients in Ho Chi Minh City, Vietnam. Am J Trop Med
Hyg 84: 127–134.
11. Rico-Hesse R, Harrison LM, Salas RA, Tovar D, Nisalak A, et al. (1997) Origins
of dengue type 2 viruses associated with increased pathogenicity in the Americas.
Virology 230: 244–251.
12. Guzman MG, Halstead SB, Artsob H, Buchy P, Farrar J, et al. (2010) Dengue: A
continuing global threat. Nat Rev Microbiol 8: S7–16.
13. Vaughn DW, Green S, Kalayanarooj S, Innis BL, Nimmannitya S, et al. (2000)
Dengue viremia titer, antibody response pattern, and virus serotype correlate
with disease severity. J Infect Dis 181: 2–9.
14. Libraty DH, Endy TP, Houng HS, Green S, Kalayanarooj S, et al. (2002)
Differing influences of virus burden and immune activation on disease severity in
secondary dengue-3 virus infections. J Infect Dis 185: 1213–1221.
Virologic Markers in Travelers’ Dengue
PLOS ONE | www.plosone.org 7 June 2013 | Volume 8 | Issue 6 | e65900
15. Libraty DH, Young PR, Pickering D, Endy TP, Kalayanarooj S, et al. (2002)
High circulating levels of the dengue virus nonstructural protein NS1 early in
dengue illness correlate with the development of dengue hemorrhagic fever.
J Infect Dis 186: 1165–1168.
16. Tricou V, Minh NN, Farrar J, Tran HT, Simmons CP. (2011) Kinetics of
viremia and NS1 antigenemia are shaped by immune status and virus serotype
in adults with dengue. PLoS Negl Trop Dis 5: e1309.
17. Duyen HT, Ngoc TV, Ha do T, Hang VT, Kieu NT, et al. (2011) Kinetics of
plasma viremia and soluble nonstructural protein 1 concentrations in dengue:
Differential effects according to serotype and immune status. J Infect Dis 203:
1292–1300.
18. Chau TN, Anders KL, Lien le B, Hung NT, Hieu LT, et al. (2010) Clinical and
virological features of dengue in Vietnamese infants. PLoS Negl Trop Dis 4:
e657.
19. Duong V, Ly S, Lorn Try P, Tuiskunen A, Ong S, et al. (2011) Clinical and
virological factors influencing the performance of a NS1 antigen-capture assay
and potential use as a marker of dengue disease severity. PLoS Negl Trop Dis 5:
e1244.
20. Lehtinen VA, Huhtamo E, Siikama¨ki H, Vapalahti O. (2008) Japanese
encephalitis in a Finnish traveler on a two-week holiday in Thailand. J Clin
Virol 43: 93–95.
21. Huhtamo E, Hasu E, Uzcategui NY, Erra E, Nikkari S, et al. (2010) Early
diagnosis of dengue in travelers: Comparison of a novel real-time RT-PCR, NS1
antigen detection and serology. J Clin Virol 47: 49–53.
22. WHO. (1997) Dengue haemorrhagic fever: diagnosis, treatment, prevention and
control, 2nd ed. Geneva, World Health Organization.
23. Vene S, Mangiafico J, Niklasson B. (1995) Indirect immunofluorescence for
serological diagnosis of dengue virus infections in Swedish patients. Clin Diagn
Virol 4: 43–50.
24. Lanciotti RS, Calisher CH, Gubler DJ, Chang GJ, Vorndam AV. (1992) Rapid
detection and typing of dengue viruses from clinical samples by using reverse
transcriptase-polymerase chain reaction. J Clin Microbiol 30: 545–551.
25. Huhtamo E, Uzcategui NY, Siikamaki H, Saarinen A, Piiparinen H, et al. (2008)
Molecular epidemiology of dengue virus strains from Finnish travelers. Emerg
Infect Dis 14: 80–83.
26. Scaramozzino N, Crance JM, Jouan A, DeBriel DA, Stoll F, et al. (2001)
Comparison of flavivirus universal primer pairs and development of a rapid,
highly sensitive heminested reverse transcription-PCR assay for detection of
flaviviruses targeted to a conserved region of the NS5 gene sequences. J Clin
Microbiol 39: 1922–1927.
27. R Development Core Team. (2011) R: A language and environment for
statistical computing. R foundation for statistical computing. 2.13.0.
28. Wood S. (2011) gamm4: Generalized additive mixed models using mgcv and
lme4. R package version 0.1–2.
29. Burnham KP, Anderson DR. (2000) Model selection and inference : A practical
information-theoretic approach. New York (NY): Springer. 353.
30. Barton K. (2011) MuMIn: Multi-model inference. R package version 1.0.0.
31. Dussart P, Labeau B, Lagathu G, Louis P, Nunes MR, et al. (2006) Evaluation of
an enzyme immunoassay for detection of dengue virus NS1 antigen in human
serum. Clin Vaccine Immunol 13: 1185–1189.
32. Alcon S, Talarmin A, Debruyne M, Falconar A, Deubel V, et al. (2002)
Enzyme-linked immunosorbent assay specific to dengue virus type 1 nonstruc-
tural protein NS1 reveals circulation of the antigen in the blood during the acute
phase of disease in patients experiencing primary or secondary infections. J Clin
Microbiol 40: 376–381.
33. Hu D, Di B, Ding X, Wang Y, Chen Y, et al. (2011) Kinetics of non-structural
protein 1, IgM and IgG antibodies in dengue type 1 primary infection. Virol J 8:
47.
34. Fox A, Le NM, Simmons CP, Wolbers M, Wertheim HF, et al. (2011)
Immunological and viral determinants of dengue severity in hospitalized adults
in Ha Noi, Viet Nam. PLoS Negl Trop Dis 5: e967.
35. Hunsperger EA, Yoksan S, Buchy P, Nguyen VC, Sekaran SD, et al. (2009)
Evaluation of commercially available anti-dengue virus immunoglobulin M tests.
Emerg Infect Dis15: 436–440.
36. Fry SR, Meyer M, Semple MG, Simmons CP, Sekaran SD, et al. (2011) The
diagnostic sensitivity of dengue rapid test assays is significantly enhanced by
using a combined antigen and antibody testing approach. PLoS Negl Trop Dis
5: e1199.
37. Lindegren G, Vene S, Lundkvist A, Falk KI. (2005) Optimized diagnosis of acute
dengue fever in Swedish travelers by a combination of reverse transcription-PCR
and immunoglobulin M detection. J Clin Microbiol 43: 2850–2855.
Virologic Markers in Travelers’ Dengue
PLOS ONE | www.plosone.org 8 June 2013 | Volume 8 | Issue 6 | e65900
